Frequency and spectrum of cancers in the Peutz-Jeghers syndrome

Johns Hopkins University, Baltimore, Maryland, United States
Clinical Cancer Research (Impact Factor: 8.19). 06/2006; 12(10):3209-15. DOI: 10.1158/1078-0432.CCR-06-0083
Source: PubMed

ABSTRACT Although an increased cancer risk in Peutz-Jeghers syndrome is established, data on the spectrum of tumors associated with the disease and the influence of germ-line STK11/LKB1 (serine/threonine kinase) mutation status are limited.
We analyzed the incidence of cancer in 419 individuals with Peutz-Jeghers syndrome, and 297 had documented STK11/LKB1 mutations.
Ninety-six cancers were found among individuals with Peutz-Jeghers syndrome. The risk for developing cancer at ages 20, 30, 40, 50, 60, and 70 years was 2%, 5%, 17%, 31%, 60%, and 85%, respectively. The most common cancers represented in this analysis were gastrointestinal in origin, gastroesophageal, small bowel, colorectal, and pancreatic, and the risk for these cancers at ages 30, 40, 50, and 60 years was 1%, 9%, 15%, and 33%, respectively. In women with Peutz-Jeghers syndrome, the risk of breast cancer was substantially increased, being 8% and 31% at ages 40 and 60 years, respectively. Kaplan-Meier analysis showed that cancer risks were similar in Peutz-Jeghers syndrome patients with identified STK11/LKB1 mutations and those with no detectable mutation (log-rank test of difference chi2 = 0.62; 1 df; P = 0.43). Furthermore, the type or site of STK11/LKB1 mutation did not significantly influence cancer risk.
The results from our study provide quantitative information on the spectrum of cancers and risks of specific cancer types associated with Peutz-Jeghers syndrome.

  • Source
    • "nsequence of inactivating mutations in the LKB1 gene ( Wang and Guan 2009 ) . The LKB1 gene is mutated in Peutz – Jeghers syndrome ( PJS ) patients ( Hemminki et al . 1998 ) . This disorder is characterized by benign pol - yps in the gastrointestinal tract and increased predisposi - tion to development of malignant tumors in a variety of tissues ( Hearle et al . 2006 ) . PJS , Cowden disease , and tuberous sclerosis patients share a large number of clini - cal features . Cowden disease and tuberous sclerosis are characterized by the hyperactivation of mTORC1 owing to the mutations in PTEN or tuberous sclerosis com - plex 1 / 2 , respectively ( Short et al . 1995 ; Liaw et al . 1997 ; Stambolic et al"
    [Show abstract] [Hide abstract]
    ABSTRACT: mRNA translation is the most energy-consuming process in the cell and strongly correlates with cellular metabolic activity. Translation and energy metabolism play important roles in homeostatic cell growth and proliferation, and when dysregulated lead to cancer. eIF4E is a key regulator of translation, which promotes oncogenesis by selectively enhancing translation of a subset of tumor-promoting mRNAs (e.g., cyclins and c-myc). PI3K/AKT and mitogen-activated protein kinase (MAPK) pathways, which are strongly implicated in cancer etiology, exert a number of their biological effects by modulating translation. The PI3K/AKT pathway regulates eIF4E function by inactivating the inhibitory 4E-BPs via mTORC1, whereas MAPKs activate MAP kinase signal-integrating kinases 1 and 2, which phosphorylate eIF4E. In addition, AMP-activated protein kinase, which is a central sensor of the cellular energy balance, impairs translation by inhibiting mTORC1. Thus, eIF4E plays a major role in mediating the effects of PI3K/AKT, MAPK, and cellular energetics on mRNA translation.
    Cold Spring Harbor Symposia on Quantitative Biology 11/2011; 76:355-67. DOI:10.1101/sqb.2011.76.010785
  • Source
    • "LKB1 mutations may be early events in NSCLC as mutation frequency does not correlate with clinical stage [14]. These observations suggest that carriers of germline LKB1 mutations should be at high risk of NSCLC which has not been noted in PJS patients [7]. Possible explanations might be altered smoking behavior or decreased life expectancy of PJS patients. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The LKB1 tumor suppressor gene is frequently mutated in sporadic lung adenocarcinomas and cervical cancers and germline mutations are causative for Peutz-Jeghers syndrome characterized by gastrointestinal polyposis. The intracellular LKB1 kinase is implicated in regulating polarity, metabolism, cell differentiation, and proliferation - all functions potentially contributing to tumor suppression. LKB1 acts as an activating kinase of at least 14 kinases mediating LKB1 functions in a complex signaling network with partial overlaps. Regulation of the LKB1 signaling network is highly context dependent, and spatially organized in various cellular compartments. Also the mechanisms by which LKB1 activity suppresses tumorigenesis is context dependent, where recent observations are providing hints on the molecular mechanisms involved.
    FEBS letters 12/2010; 585(7):944-51. DOI:10.1016/j.febslet.2010.12.034 · 3.34 Impact Factor
  • Source
    • "In humans, germline mutation of LKB1 results in the Peutz- Jeghers syndrome, a familial cancer syndrome characterized by intestinal hamartomas and an increased risk for epithelial cancers, including lung cancers (Hearle et al., 2006). The LKB1 gene encodes a serine/threonine kinase that phosphorylates several substrates, many of which are also kinases (Alessi et al., 2006). "
    [Show abstract] [Hide abstract]
    ABSTRACT: In mice, Lkb1 deletion and activation of Kras(G12D) results in lung tumors with a high penetrance of lymph node and distant metastases. We analyzed these primary and metastatic de novo lung cancers with integrated genomic and proteomic profiles, and have identified gene and phosphoprotein signatures associated with Lkb1 loss and progression to invasive and metastatic lung tumors. These studies revealed that SRC is activated in Lkb1-deficient primary and metastatic lung tumors, and that the combined inhibition of SRC, PI3K, and MEK1/2 resulted in synergistic tumor regression. These studies demonstrate that integrated genomic and proteomic analyses can be used to identify signaling pathways that may be targeted for treatment.
    Cancer cell 06/2010; 17(6):547-59. DOI:10.1016/j.ccr.2010.04.026 · 23.89 Impact Factor
Show more